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Leukemia stem cells (LSCs) play a pivotal role in the
resistance of chronic myeloid leukemia (CML) to
tyrosine kinase inhibitors (TKIs) and its progression
to blast crisis (BC), in part, through the alternative
splicing of self-renewal and survival genes. To eluci-
date splice-isoform regulators of human BC LSC
maintenance, we performed whole-transcriptome
RNA sequencing, splice-isoform-specific quantita-
tive RT-PCR (qRT-PCR), nanoproteomics, stromal
coculture, and BC LSC xenotransplantation anal-
yses. Cumulatively, these studies show that the
alternative splicing of multiple prosurvival BCL2
family genes promotes malignant transformation of
myeloid progenitors into BC LSCS that are quiescent
in the marrow niche and that contribute to thera-
peutic resistance. Notably, sabutoclax, a pan-BCL2
inhibitor, renders marrow-niche-resident BC LSCs
sensitive to TKIs at doses that spare normal progen-
itors. These findings underscore the importance of
alternative BCL2 family splice-isoform expression
in BC LSC maintenance and suggest that the combi-
natorial inhibition of prosurvival BCL2 family proteins
and BCR-ABL may eliminate dormant LSCs and
obviate resistance.
INTRODUCTION
Human leukemia stem cells (LSCs), first described in acute
myeloid leukemia (AML) (Lapidot et al., 1994), subvert stem316 Cell Stem Cell 12, 316–328, March 7, 2013 ª2013 Elsevier Inc.cell properties, such as quiescence, enhanced self-renewal,
and survival, which renders them resistant to conventional
therapy (Guzman et al., 2002; Visvader, 2011). Chronic myeloid
leukemia (CML) represents an important paradigm for dissecting
the molecular evolution of LSCs during leukemic progression
and the role of LSCs in therapeutic resistance because CML
was the first malignancy to be targeted with therapy that selec-
tively inhibits the aberrant kinase responsible for CML initiation
(Druker et al., 2001). Although BCR-ABL-targeted tyrosine
kinase inhibitors (TKIs) eradicate the bulk of BCR-ABL1-
expressing cells, they frequently fail to eliminate quiescent,
niche-resident LSCs that drive relapse (Abe et al., 2008; Barnes
and Melo, 2006; Chomel et al., 2011; Corbin et al., 2011) and
blast crisis (BC) transformation after TKI discontinuation (Chomel
and Turhan, 2011; Cortes et al., 2004; Deininger, 2008; Stuart
et al., 2009). Despite improvements in overall survival (Druker
et al., 2006), no curative pharmacologic therapy for CML exists,
partly because the genetic and epigenetic drivers of human BC
LSC generation remain to be elucidated.
In human BC CML, and in many cases of AML, LSCs are
enriched within the CD34+CD38+Lin compartment, which is
composed predominantly of granulocyte-macrophage progeni-
tors (GMPs) (Eppert et al., 2011; Goardon et al., 2011; Jamieson
et al., 2004) with an aberrant self-renewal capacity. Serial trans-
plantation experiments show that as few as 1,000 GMPs
serially transplant human BC CML (Abrahamsson et al., 2009).
Moreover, GMP LSCs have been identified in transgenic mouse
models of both BC CML (Jaiswal et al., 2003) and AML (Krivtsov
et al., 2006), suggesting that malignant transformation of pro-
genitors into LSC, through aberrant acquisition of stem cell
properties, is a key driver of leukemic progression.
Evidence from primary patient samples demonstrates that
chronic phase (CP) CML is a clonal disorder (Martin et al.,
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ing hematopoietic stem cells (HSCs) (Jamieson et al., 2004).
Although necessary for CP initiation, BCR-ABL expression is
not sufficient to drive BC transformation (Radich et al., 2006).
Both mouse transgenic models and xenotransplantation data
show that the activation of stem cell signaling pathways,
including the Wnt/b-catenin pathway (Abrahamsson et al.,
2009; Jamieson et al., 2004; McWeeney et al., 2010; Zhao
et al., 2007), the hedgehog signaling pathway (Zhao et al.,
2009), and the intrinsic apoptotic pathway regulated by the
BCL2 gene family (Jaiswal et al., 2003), promote BC transforma-
tion. Malignant transformation of BCR-ABL1-expressing GMPs
into self-renewing BC LSCs (CD34+CD38+Lin) occurs, in
some cases, as a consequence of the alternative splicing of
GSK3b, a negative regulator of Wnt/b-catenin, hedgehog sig-
naling, and MCL1 (Abrahamsson et al., 2009; Ding et al., 2007).
Whereas recent reports reveal that mutations in splicing genes
promote the progression of myeloid malignancies to acute
leukemia (Yoshida et al., 2011), alternative-splicing-mediated
alterations in the transcriptome may also enable BC transforma-
tion in a malignant microenvironment.
Because CML becomes increasingly refractory to TKIs during
progression to BC (Karbasian Esfahani et al., 2006; Sawyers
et al., 2002), understanding the epigenetic mechanisms that
drive BC LSC maintenance and contribute to therapeutic resis-
tance is essential. In addition, several studies suggest that LSC
quiescence induction by the stem cell niche is a major compo-
nent of therapeutic resistance (Barnes and Melo, 2006; Corbin
et al., 2011; Forsberg et al., 2010; Holyoake et al., 1999; Saito
et al., 2010). Although recent evidence shows that increased
expression of BCL2 family members contributes to CML patho-
genesis (Aichberger et al., 2005; Dai et al., 2004; Tauchi et al.,
2003), the precise nature of BCL2 splice-isoform usage had
not been examined, even though a number of isoforms have anti-
thetical functions (Akgul et al., 2004).
Prosurvival BCL2 family genes contribute to leukemogenesis
(Beverly and Varmus, 2009), CML progression (Jaiswal et al.,
2003), TKI resistance (Aichberger et al., 2005; Horita et al.,
2000; Jaiswal et al., 2003; Konopleva et al., 2002; Sa´nchez-
Garcı´a and Gru¨tz, 1995), and HSC and progenitor cell survival
(Domen and Weissman, 2003; Milyavsky et al., 2010) by direct
inhibition of mitochondrial outer-membrane permeabilization.
Expression of BCL2 family genes has also been linked to
bone-marrow-niche-dependent TKI resistance in vitro (Bewry
et al., 2008). However, whether prosurvival BCL2 family gene
splice-isoform expression promotes human BC LSC mainte-
nance has not been elucidated. Moreover, the role of niche-
dependent BCL2 family gene expression has not been delin-
eated in the context of BC LSC quiescence induction and TKI
resistance in vivo. Thus, we compared BCL2 family expression
in fluorescence-activated cell sorting (FACS)-purified CML
progenitors from normal, CP, and BC patients and in BC LSCs
engrafted in different hematopoietic niches. We also investi-
gated whether BC LSCs could be targeted with sabutoclax,
a pan-BCL2 inhibitor capable of inhibiting BCL2, MCL1, BFL1,
and BCLXL. Finally, the capacity of pan-BCL2 inhibition to
overcome niche-dependent TKI resistance was assessed both
in vitro and in BC LSC xenograft models as a paradigm for under-
standing the potential utility of sabutoclax in the sensitization ofCquiescent cancer stem cells (CSCs) to antiproliferative agents in
a broad array of malignancies.
RESULTS
Prosurvival BCL2 Isoform Expression Increases during
BC Transformation
Although several studies have linked BCL2 gene upregulation
with CML progression, most have focused on BCR-ABL-ex-
pressing cell lines (Amarante-Mendes et al., 1998; Gesbert and
Griffin, 2000; Sa´nchez-Garcı´a and Gru¨tz, 1995) or bulk CD34+
cells (Aichberger et al., 2005; Horita et al., 2000; Radich et al.,
2006) rather than self-renewing human BC LSCs (CD34+CD38+
Lin) that promote BC transformation. Even though many
BCL2 family genes encode splice variants with both proapopto-
tic and antiapoptotic functions (Moore et al., 2010), relatively little
is known about the pattern of BCL2 family gene isoform ex-
pression in human BC LSCs. Therefore, we utilized splice-
isoform-specific quantitative RT-PCR (qRT-PCR) and whole-
transcriptome RNA sequencing (RNA-seq) to analyze BCL2
family isoform expression in FACS-purified progenitors from
primary normal (n = 6), CP (n = 8), and BC (n = 9) human samples
(Table S1 available online). Notably, BC LSCs expressed signif-
icantly higher levels of BCR-ABL and prosurvival BCL2L,MCL1L,
BCLXL, and BFL1L splice-isoforms than did CP progenitors (Fig-
ure 1A), as well as higher BCL2L, BCLXL, and BFL1L than did
normal progenitors (Figures S1A and S1B). Both qRT-PCR
and RNA-seq revealed a relative abundance of antiapoptotic
MCL1-long compared with proapoptotic short isoforms in BC
LSCs (Figures 1B, 1C, S1A, and S1B). These data suggest that
prosurvival BCL2 family gene isoforms are globally upregulated
during CML BC transformation.
Because BCR-ABL induces BCL2 family gene expression
in CML cell lines (Aichberger et al., 2005; Horita et al., 2000;
Sa´nchez-Garcı´a and Gru¨tz, 1995), we examined whether prosur-
vival BCL2 family overexpression coincided with BCR-ABL
amplification in sorted CML progenitors. A striking correlation
was observed between BCR-ABL and BCLXL levels in CML
progenitors, which was confirmed in lentiviral BCR-ABL-trans-
duced progenitors (Figure 1D), suggesting that increased BCLXL
expression is driven by BCR-ABL amplification in BC LSCs, as
previously reported (Aichberger et al., 2005; Horita et al.,
2000; Sa´nchez-Garcı´a and Gru¨tz, 1995). Expression of other
prosurvival BCL2 family gene isoforms did not correlate with
BCR-ABL, indicating that upregulation occurs through BCR-
ABL-independent mechanisms. Consistent with qRT-PCR
results, an increase in BCL2 and MCL1 proteins was detected
by FACS analysis in BC LSCs compared with CP progenitors
(Figures 1E and S1C). Notably, BCL2 protein expression was
higher in serially transplantable CD34+CD38+Lin BC LSCs
than in normal or CP CD34+CD38Lin and CD34+CD38+Lin
cells (Figure S1D). Moreover, increased expression of both
BCL2 transcript and protein levels correlated with the expansion
of CD123+ GMP BC LSCs (Figures S1–S1F), suggesting that
BCL2 overexpression portends CML progression. In addition
to the increased prosurvival BCL2 family gene expression
detected by RNA-seq (Figure S1G), an apoptosis qRT-PCR array
demonstrated that BC LSCs harbored distinct expression
patterns of prodeath BCL2 family genes as well as TP53 andell Stem Cell 12, 316–328, March 7, 2013 ª2013 Elsevier Inc. 317
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Figure 1. Prosurvival BLC2 Isoform Expres-
sion Increases Curing Blast Crisis Transfor-
mation
(A) Quantitative RT-PCR (qRT-PCR) of prosurvival
(long isoforms) BCL2, MCL1, BCLX, BFL1, and
BCR-ABL messenger RNAs (mRNAs) in primary
chronic phase (CP; black, n = 13) and blast crisis
(BC; red, n = 11) progenitors. Values are normal-
ized to human HPRT mRNA expression. Graphs
show mean ± SEM; *, p < 0.05 by unpaired t test.
(B) Relative ratio ofMCL1 long to short isoforms in
normal (n = 7) and BC (n = 8) progenitors. Graph
showsmean ± SEM; **, p < 0.01 by unpaired t test.
(C) Whole-transcriptome sequencing of fluores-
cence-activated cell sorting (FACS)-sorted pro-
genitor cells from a normal and a BC sample
showing quantification of MCL1L and MCL1S iso-
forms in each sample. Graph shows fragments per
kilobase of exon per million fragments mapped
(FPKM) ± 95% confidence interval.
(D) Correlation between BCR-ABL mRNA ex-
pression and BCLXL mRNA expression in pro-
genitors. Primary CP and BC samples (n = 20; left).
BCR-ABL transduced normal progenitor colonies
(n = 12; right). Both graphs depict best-fit line and
95% confidence intervals by Pearson correlation
analysis.
(E) Representative FACS histograms of BCL2 and
MCL1 protein expression in CP progenitors (black)
versus BC progenitors (red). Fluorescence minus
one (FMO) controls are shown in gray.
(F) Full-transcriptome RNA sequencing analysis of
survival-pathway genes in FACS-sorted (CD45+
CD34+CD38+Lin) progenitors from three normal
cord blood (CB), three normal adult peripheral
blood (NP), eight CP, one lymphoid BC (LBC), and
eight BC samples. The heat map depicts log2-fold
FPKM.BCL2 family genes are highlighted and their
functions are indicated by blue (prosurvival) or
orange (prodeath) coloring.
(G) Unsupervised principal component analyses
of the survival pathway genes for FACS-sorted
CD45+CD3 4+CD38+Lin progenitors from three
CB, three NP, eight CP, one LBC, and eight BC
samples.
See also Figure S1 and Tables S1 and S2.
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components of the extrinsic apoptotic machinery, compared
with normal progenitors (Table S2). To gain further insight into
the role of survival regulators in BC transformation, we per-
formed RNA-seq analysis on FACS-purified CD34+CD38+Lin
normal, CP, and BC samples (Table S1). Both heatmap (Fig-
ure 1F) and unsupervised principal component (Figure 1G) anal-
ysis revealed that survival-related gene expression distinguished
BC LSCs from CP LSCs as well as TKI-treated and normal
progenitor samples. Together, these data suggest that a distinct
survival gene signature predicts LSC generation and BC
transformation.
Quiescent BC LSCs Engraft the Bone Marrow Niche and
Are TKI Resistant
Previous research demonstrated a link between BCL2 family
member expression and the arrest of cells in G0 or G1 of the318 Cell Stem Cell 12, 316–328, March 7, 2013 ª2013 Elsevier Inc.cell cycle (Zinkel et al., 2006; Vairo et al., 1996). In T and B cells
of BCL2 transgenic mice, higher BCL2 expression correlated
with a higher G0 or G1 fraction, a lower S phase fraction, and
decreased BrdU incorporation (O’Reilly et al., 1997a; O’Reilly
et al., 1997b; O’Reilly et al., 1996). Moreover, enforced BCL2
expression was recently shown to restore quiescence of progen-
itors in a mouse model of myelodysplastic syndrome (Slape
et al., 2012). Seminal studies also show that quiescent LSCs
are TKI resistant (Barnes and Melo, 2006; Bewry et al., 2008;
Holyoake et al., 1999; Saito et al., 2010).
To analyze the capacity of various hematopoietic niches to
maintain dormant LSCs, human BC CD34+ cells, labeled with
a membrane-bound fluorescent dye, DiR, which is retained by
nondividing cells, were transplanted into neonatal RAG2/gc
/
mice (Abrahamsson et al., 2009). Within 10 weeks, transplanted
mice developed BC CML typified by myeloid sarcoma forma-
tion as well as robust liver, spleen, blood, and bone marrow
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revealed that marrow-engrafted BC LSCs harbored higher levels
of DiR fluorescence than those in other niches (Figure 2A),
corresponding to a distinct population of G0 (Ki67
low7-AADlow)
progenitors (Figures 2B and 2C) in the marrow. Confocal fluores-
cence microscopic and immunohistochemical (IHC) analysis
revealed dormant pHis-H3Ki-67low human CD45+CD34+CD38+
cells adjacent to the marrow endosteal region (Figures 2D, 2E,
S3A, and S3B), as previously reported in AML LSC xenograft
models (Saito et al., 2010). Moreover, FACS analysis revealed
that CD34+CD38+CD123+CD45RA+Lin (GMP) BC LSCs, previ-
ously shown to harbor the greatest serial-transplantation
potential, were more prevalent in the marrow than in other
hematopoietic niches (Figure S3C). In addition, cell-cycle FACS
analysis revealed that a proportion of quiescent BC LSCs was
enriched in the marrow compared to the splenic niche (Figures
S3D and S3E).
To examine the capacity of TKIs to eliminate quiescent self-
renewing BC LSCs, RAG2/gc/, mice were transplanted
with human BC CD34+ cells and treated orally with dasatinib,
a potent BCR-ABL-targeted TKI (Figure S4A). Transplantation
resulted in robust engraftment of human CD45+ cells (Figures
3A, 3B, S2A and S2B) and BC LSCs (CD34+CD38+Lin) in
medullary and extramedullary microenvironments (Figures 3B–
3D and S3). Although dasatinib treatment (50 mg/kg) signifi-
cantly reduced the CD45+ leukemic burden compared with
vehicle-treated controls (Figures 3E and S4B–S4D), a dasati-
nib-resistant BC LSC population persisted in the marrow
(Figures 3C, 3F, and S4E). Following dasatinib treatment, nano-
proteomic analysis of FACS-purified-marrow-derived BC LSCs
revealed a significant reduction in the phosphorylation of
CRKL, a direct substrate of the BCR-ABL kinase (Figures 3G
and 3H; Goldman and Brender, 2000), indicative of adequate
BCR-ABL kinase inhibition. However, cell-cycle FACS analysis
demonstrated an increase in quiescence (Figures 3I–3J), sug-
gesting that quiescent BC LSCs are resistant to BCR-ABL
kinase inhibition and enriched in the marrow niche, thereby
providing a reservoir for relapse.
Marrow-Niche-Engrafted BC LSCs Have a Prosurvival
Gene Signature
Because BCL2 overexpression has been linked to apoptosis
and TKI resistance in mouse transgenic models and cell lines
(Amarante-Mendes et al., 1998; Domen and Weissman, 2003;
Konopleva et al., 2002), we hypothesized that prosurvival
BCL2 family gene expression is enhanced in marrow-engrafted
BC LSCs and that they harbor greater TKI resistance than those
in other niches. Comparative apoptosis qRT-PCR array analysis
performed on FACS-purified CD45+CD34+CD38+Lin cells re-
vealed that, while BCLX, BFL1, and BCLW were not differen-
tially expressed, BCL2 was significantly upregulated in marrow
compared with spleen tissue (Figures 4A–4B), as was the
expression of the prosurvival isoforms of MCL1 and BFL1
(Figures S5A and S5B), thereby favoring BC LSC survival. Simi-
larly, RNA-seq revealed increased BCL2 and decreased BIM
expression in marrow-engrafted BC LSCs compared to BC
LSCs before transplantation (Figure S5C). To further support
these findings, gene set enrichment analysis (GSEA) of RNA-
seq data demonstrated that cell-cycle checkpoint and cell-Ccycle arrest genes were upregulated in FACS-purified BC
LSCs compared with their normal counterparts (Figure S5D).
Finally, BCL2 protein expression was significantly higher in
marrow-engrafted BC LSCs than in non-LSCs (human CD45+
CD34 cells) in the same niche and correlated with a decreased
sensitivity to dasatinib treatment (Figures S5E and S5F). Thus,
marrow-niche-resident BC LSCs express high levels of prosur-
vival BCL2 family gene isoform expression, leading to enhanced
TKI resistance.
Both IHC and confocal fluorescence microscopic analysis
demonstrated that human BCL2 and MCL1 protein expression
(Figure 4C) colocalized with humanCD34- and CD38-expressing
cells in the marrow endosteal niche (Figure 4D). Interestingly,
BCL2- and MCL1-expressing human BC CD34+ cells were
enriched in the femoral epiphysis, a preferential site for homing,
proliferation, and survival of human leukemia cells following xen-
otransplantation (Figure S5G; Ninomiya et al., 2007). Dasatinib
treatment increased BCL2 and MCL1 expression and reduced
Ki67 (Figures S5H and S5I), consistent with FACS analyses
showing an increase in the proportion of quiescent BC LSCs
after TKI treatment (Figure 3I–3J). Although TKIs effectively elim-
inate LSCs in extramedullary microenvironments, they fail to
eradicate quiescent, BCL2- and MCL1-expressing BC LSCs
from the marrow niche.
Sabutoclax Inhibits BC LSC Survival
Detection of increased prosurvival BCL2 isoforms in primary BC
samples as well as enhanced BCL2 and MCL1 expression in
marrow-engrafted BC LSCs, particularly following dasatinib
treatment (Figure S4), provided the impetus for testing the LSC
inhibitory capacity of sabutoclax, an optically pure derivative of
apogossypol that inhibits all prosurvival BCL2 family proteins
(Wei et al., 2009; Wei et al., 2010; Figure 5A). Sabutoclax treat-
ment increased the apoptosis of BC LSCs in a dose-dependent
manner in vitro, as measured by cleaved capase-3 and propi-
dium iodide staining (Figure 5B). Because BC LSCs were
TKI-resistant in the marrow niche, the anti-LSC efficacy of sabu-
toclax was tested in a genetically engineered SL and M2 stromal
coculture system that secretes human SCF, IL-3, and G-CSF
and supports the long-term survival of self-renewing BC LSCs
(Hogge et al., 1996; Figure S6A). Despite the induction of prosur-
vivalBCL2 family gene expression in BC LSC-supportive stromal
cocultures (Figure S6B), sabutoclax reduced LSC survival and
colony-forming capacity (Figures 5C, 5D and S6A) at doses
that spared normal progenitors (Figures 5C and 5D; Table S4).
Moreover, lentiviral-mediated short-hairpin RNA knockdown of
BCL2 reduced the colony-forming capacity of BC LSCs but
not of normal progenitors (Figures 5E and 5F). However, BCL2
knockdown did not completely abrogate BC LSC colony forma-
tion, suggesting that inhibition of multiple BCL2 family proteins,
including MCL1, is required in order to eradicate BC LSCs in
supportive niches.
To further assess the role of BCL2 in BC LSC survival, ABT-
737, a potent BCL2 and BCLXL inhibitor, was utilized in parallel
stromal coculture experiments. Fluorescence polarization
assays demonstrated that sabutoclax and ABT-737 dissociate
a BIM peptide from BCL2 and BCLXL at nanomolar concen-
trations. However, only sabutoclax effectively displaces BIM
fromMCL1 and BFL1 (Figures S6C and S6D; Table S4). Becauseell Stem Cell 12, 316–328, March 7, 2013 ª2013 Elsevier Inc. 319
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Figure 2. Quiescent BC LSCs Engraft the Bone Marrow Niche
(A) Retained DiR fluorescence of BC progenitors (CD45+CD34+CD38+Lin) engrafted in tumor (n = 4), liver (n = 4), spleen (n = 3), and bonemarrow (n = 2) 18weeks
after DiR surface staining and transplant. Graph shows mean ± SEM; ***, p < 0.001 by ANOVA and Tukey post hoc analysis.
(B) Representative FACS plots showing gating and cell-cycle analysis of live (propidium iodide negative [Pi]), bone marrow-engrafted BC progenitors
(CD45+CD34+CD38+Lin). FMO gating controls are shown in the top row, and engrafted bone marrow is shown in the bottom row.
(C) Quantification of BC progenitors in untreated marrow in the different phases of the cell cycle. n = 10 engrafted bones. Graph shows mean ±SEM.
(D–E) Histological analysis of engrafted bonemarrow showing hematoxylin and eosin (H&E), humanCD34, CD38 and Ki67, and pHis-H3 staining. The dotted lines
delineate the endosteum (50 mm from the bone edge). Scale bars represent 50 mm.
See also Figures S2 and S3 and Table S3.
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Figure 3. Marrow-Engrafted Quiescent BC
LSCs Are TKI Resistant
(A) Representative FACS plots (live cells [PI])
showing human CD45 engraftment in mouse
bone marrow. Percentages shown are based on
parental population as indicated.
(B) Total human CD45 engraftment in liver, spleen,
blood, and bone marrow of BC-transplanted mice
(n = 31) for 3 different CML BC patients samples.
Graphs show mean ± SEM.
(C) Representative FACS plots showing human BC
progenitors (CD45+CD34+CD38+Lin) engraft-
ment in mouse bone marrow.
(D) Total engraftment of progenitors in the hema-
topoietic organs of BC transplanted mice (n = 31)
for 3 different CML BC patient samples. Values are
aback-gated calculation, basedon thepercentage
of CD45+ cells = (percentage of CD45+ cells) 3
(percentage of CD34+CD38+ cells). Graphs show
mean ± SEM.
(E) Relative engraftment (percent of vehicle treated
controls) of humanCD45 cells in the hematopoietic
organs following treatment with vehicle (n = 13) or
dasatinib (50 mg/kg, n = 14). Statistical analysis is
shown comparing the residual engraftment in each
tissue (gray bars) and depicts the results of ANOVA
with Tukey post hoc comparisons; *, p < 0.05.
Graphs show mean ± SEM.
(F) Relative engraftment (percentage of vehicle
treated controls) of progenitors in the hemato-
poietic organs following treatment with vehicle
(n = 19) or dasatinib (n = 19). Statistical analysis is
shown comparing the residual engraftment in
each tissue (gray bars) and depicts the results of
ANOVA with Tukey post hoc comparisons; ***, p <
0.001. Graphs show mean ± SEM.
(G) Representative proteomics plots showing the
analysis of phosphorylated CRKL (left) and b2
microglobulin (right) in BC progenitors sorted from
engrafted mouse bone marrow and after treat-
ment with either vehicle or dasatinib.
(H) Quantification of the total area under the curve
(AUC) of phosphorylated CRKL peaks in vehicle-
(n = 5) and dasatinib- (n = 5) treated samples. All
values are normalized to b2 microglobulin protein
expression in the same sample. Graphs show
mean ± SEM.
(I) Representative FACS-cell-cycle plots of live CD45+ BC progenitors engrafted in marrow following vehicle and dasatinib treatment.
(J) Cell-cycle status of live CD45+ BC progenitors sorted from the marrow and following treatment with vehicle (n = 10) or dasatinib (n = 10). All graphs in Figure 3
show mean ± SEM. All statistical analyses are by unpaired t test unless otherwise specified.
See also Figure S4.
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Leukemia Stem Cell Elimination with a Pan-BCL2 InhibitorABT-737 resistance is associated with increased MCL1 and
BFL1 expression (Vogler et al., 2009a; Yecies et al., 2010) and
both qRT-PCR and transcriptome data showed that BC LSCs
express multiple BCL2 family members, including MCL1 and
BFL1 (Figures S5A and S5B), the anti-LSC efficacy of sabutoclax
and ABT-737 was compared. Sabutoclax reduced BC LSC
survival more than ABT-737 did at all doses tested in stromal
cocultures (Figures S6F and S6G; Table S4), even though the
activity looked comparable in stroma-independent K562 cells
(Figure S6H), thereby underscoring the importance of the niche
in BCL2 family member induction. Hence, eradication of niche-
dependent BC LSCs is predicated on the inhibition of multiple
BCL2 family proteins, including MCL1 and BFL1.CSabutoclax Sensitizes Marrow-Niche-Engrafted BC
LSCs to Dasatinib
To examine the necessity of prosurvival BCL2 family expression
for BC LSCmaintenance, we tested the efficacy of sabutoclax in
inhibiting BC LSC survival in the marrow compared with the
splenic niche (Figure 6A). In BC CD34+ cell-engrafted mice,
FACS analysis revealed that sabutoclax (5 mg/kg) reduced
LSC burden (Figure 6B; Table S5) commensurate with a decre-
ment in human BCL2- and MCL-expressing cells in the marrow
(Figures 6C and 6D). Moreover, sabutoclax treatment increased
G2/S (Figure 6E) and TUNEL
+ apoptotic cells (Figure 7A), indica-
tive of both cell-cycle and apoptosis induction. Consistent with
in vitro results, no significant reduction was observed in normalell Stem Cell 12, 316–328, March 7, 2013 ª2013 Elsevier Inc. 321
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Figure 4. Enhanced BCL2 Expression in Marrow-Niche-Engrafted BC LSCs
(A) BCL2 family RT2 Profiler PCR Array System data of FACS-sorted progenitors from engrafted mice (n = 3). The graph depicts fold expression in marrow-
engrafted progenitors relative to spleen-engrafted progenitors, which are set at 1. Graphs show mean ± SEM; p < 0.05 by unpaired t test.
(B)BCL2LmRNA isoform expression andBCL2 protein expression inmarrow- versus spleen-engrafted BCprogenitors. Statistical analyses are by unpaired t test.
(C) Representative immunohistochemical (IHC) analysis of gross (top) and endosteal (bottom) engraftment of human CD34+, BCL2+, and MCL1+ cells in mouse
bone marrow. Scale bars represent 1 mm in low-magnification images and 100 mm in high-magnification images.
(D) Representative images showing immunofluorescence analysis of hCD38+ and hBCL2+ cells in BC CML-engrafted marrow compared to nontransplant control
marrow. Scale bars represent 50 mm. The boxed area shows a closeup of the endosteal region.
See also Figure S5.
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Figure 5. Sabutoclax Inhibits BC LSC
Survival
(A) In vitro experimental design used in the present
studies.
(B) FACS analysis of activated caspase-3+ CML
progenitors following in vitro culture with BI-97C1
(sabutoclax). Graph shows mean ± SEM from
three independent experiments.
(C) FACS analysis of normal (blue) and BC (red)
progenitors cultured on SL and M2 bone marrow
stroma in the presence of sabutoclax. All values
are normalized to vehicle treated control. Graph
shows mean ± SEM from five different normal and
BC samples.
(D) Total colonies formed by normal (blue) and BC
(red) progenitors following sabutoclax treatment.
All values are normalized to vehicle-treated con-
trol. Graph showsmean ± SEM from three different
normal and three BC samples. (C) and (D) show
best-fit lines and statistical comparisons by
nonlinear regression analysis.
(E) Representative colonies from control or
shBCL2 transduced progenitors (left). qRT-PCR of
BCL2L mRNA in normal or BC cells following
transduction with control and shBCL2 lentivirus
(n = 3 colonies for each sample type; right). Graph
shows mean ± SEM.
(F) Number of colonies formed by FACS-sorted
normal (blue) or BC (red) progenitors following
transduction with control or shBCL2 lentivirus.
Graph shows average colonies per well for four
different normal and BC samples and statistical
analysis by paired t test.
See also Figure S6 and Tables S4 and S5.
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Leukemia Stem Cell Elimination with a Pan-BCL2 Inhibitorprogenitor engraftment in themarrow after sabutoclax treatment
(Figures S7B–S7D), suggesting that a reasonable therapeutic
index exists between BC LSCs and normal HSCs.
For quantification of the TKI-sensitizing effects of sabutoclax
in the presence of human BC-LSC-supportive cytokines not
present in mouse marrow, human BC LSCs from sabutoclax-
or vehicle-treated mice were FACS-sorted into SL and M2
stromal cocultures in the presence of dasatinib (Figure S7A). In
this ex vivo assay, sabutoclax-pretreated progenitors were
more sensitive to dasatinib than were vehicle-pretreated con-
trols (Figure S7B). For further examination of the synergistic
effects of sabutoclax and dasatinib, BC LSC-engrafted mice
were treated with lower-dose sabutoclax, dasatinib, or a combi-
nation of both, followed by FACS-mediated LSC analysis.
Whereas lower-dose dasatinib and sabutoclax alone had no
significant effect on marrow BC LSC engraftment, combination
treatment significantly reduced marrow LSC survival (Figure 7E;
Table S6). These results suggest that sabutoclax sensitizes
quiescent BCL2- and MCL1-expressing BC LSCs to dasatinib-
mediated cell death. Finally, the capacity of combined treatment
to eradicate self-renewing BC LSCs was assessed by trans-
planting treated marrow into secondary recipients and moni-
toring survival time. Mice transplanted with combination-treated
marrow had a significant survival advantage compared to thoseCell Stem Cell 12, 316–3that received dasatinib-treated marrow
(Figure 7F). Sabutoclax-mediated TKI
sensitization was dose (Table S6) androute-of-administration dependent, with greater bioavailability
provided by intravenous dosing, as shown by pharmacokinetic
studies (Figure S7C). More clinically applicable intravenous
dosing resulted in a significant reduction in BC LSCs after
combination sabutoclax and dasatinib therapy (Figure S7D) at
doses that spared normal hematopoietic progenitors (Figures
7C and 7D). Overall, our data demonstrate that dasatinib alone,
although effective in reducing bulk leukemic cell burden, does
not eradicate marrow-niche-resident BC LSCs. In contrast,
combined dasatinib and sabutoclax therapy significantly inhibits
both primary and serial LSC engraftment, indicative of abroga-
tion of both TKI resistance and BC LSC self-renewal.
DISCUSSION
Malignant transformation of human myeloid progenitors into BC
LSCs through alternative splicing represents a molecular mech-
anism driving CML BC transformation and therapeutic resis-
tance. By analyzing FACS-sorted, serially transplantable CD34+
CD38+Lin cells from primary patient samples, we show that BC
LSCs harbor increased expression of multiple prosurvival BCL2
family genes compared to both CP and normal progenitors.
This prosurvival gene expression is further upregulated upon
coculture with human LSC-supportive cytokine-secreting bone28, March 7, 2013 ª2013 Elsevier Inc. 323
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Figure 6. Sabutoclax Sensitizes Marrow-
Niche-Engrafted BC LSCs to Dasatinib
(A) In vivo experimental design used in the present
studies.
(B) Engraftment of BC progenitors in spleen and
bone marrow following vehicle (n = 27) and
sabutoclax treatment (5 mg/kg, n = 26). Graph
shows mean ± SEM for three different BC
patient samples and statistical analysis by Mann-
Whitney test.
(C) Representative IHC analysis of BCL2 and
MCL1 staining in engrafted bone marrow following
vehicle and sabutoclax treatment. Scale bars
represent 100 mm.
(D) Quantification of BCL2+ and MCL1+ cells in the
endosteum of engrafted bone marrow following
vehicle (n = 3) and sabutoclax (n = 3) treatment.
Graph shows mean ± SEM.
(E) FACS-cell-cycle analysis of CD45+ bone-
marrow-engrafted BC cells in vehicle- (n = 6) and
sabutoclax- (n = 5) treated mice. Graph shows
mean ± SEM. *, p < 0.05 by unpaired t test.
See also Figure S7 and Table S6.
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Leukemia Stem Cell Elimination with a Pan-BCL2 Inhibitormarrow stroma and upon engraftment in the bone marrow niche.
These data are consistent with previous reports demonstrating
increased BCL2 family expression in CML cells (Aichberger
et al., 2005; Horita et al., 2000; Sa´nchez-Garcı´a and Gru¨tz,
1995) and upregulation via niche-dependent signals (Bewry
et al., 2008). However, our study is unique in that we show that
prosurvival BCL2 family splice-isoform upregulation is present
in self-renewing BC LSCs and that niche-dependent BCL2
family expression is associated with TKI resistance in vivo. This
study represents an important whole-transcriptome and splice-
isoform-specific, qRT-PCR-based elucidation of isoform-
specific BCL2 family gene expression signatures in CML LSCs,
which is important given that the BCL2 family is spliced into
variants with antithetical functions (Akgul et al., 2004; Bingle
et al., 2000) and has potential clinical significance with regard
to predicting leukemic progression.
In a robust RAG2/gc/ xenograft model of human BC CML,
we demonstrate that BC LSCs are protected from TKI-mediated
cell death when engrafted in the marrow microenvironment as
opposed to extramedullary hematopoietic niches, suggesting
that LSCs are subject to marrow-specific cytoprotection inde-
pendent of BCR-ABL, as demonstrated by nanoproteomic phos-324 Cell Stem Cell 12, 316–328, March 7, 2013 ª2013 Elsevier Inc.pho-CRKL analysis. Although dasatinib
treatment effectively reduces leukemic
burden in engrafted mice, it does not fully
eliminate BC LSCs, as evidenced by the
fact that mice serially transplanted with
dasatinib-treated bone marrow quickly
develop BC CML. These data add to
previous findings that CML BC LSCs
also depend on BCR-ABL-independent
survival mechanisms (Corbin et al.,
2011). Our findings expand on this con-
cept by identifying prosurvival BCL2
family isoform expression as an important
niche-specific survival mechanism andmolecular target for CML BC LSC sensitization to TKI therapy.
Although lentiviral BCR-ABL transduction experiments suggest
that BCLXL expression is BCR-ABL dependent, our in vivo
studies suggest that marrow microenvironmental cues promote
splice-isoform switching that favors the expression of multiple
prosurvival BCL2 family splice-isoforms in BC LSC, thereby
providing the impetus for elucidating these extrinsic factors in
future studies.
Both cell-cycle and immunofluorescence analyses demon-
strate that quiescent CML BC LSCs engraft the marrow niche
and are enriched in the endosteal region, consistent with
previous AML xenograft studies (Saito et al., 2010). Moreover,
IHC analyses show that endosteal niche-resident BC LSCs
express prosurvival BCL2 and MCL1. Strikingly, dasatinib treat-
ment does not eliminate quiescent bone marrow BC LSCs.
These quiescent BC LSCs harbor enhanced engraftment poten-
tial (Barnes and Melo, 2006), which may explain why mice
serially transplanted with dasatinib-treated marrow still develop
BC CML.
Notably, BC LSCs in stromal coculture and in the marrow are
sensitive to sabutoclax, a pan-BCL2 inhibitor, in a dose depen-
dent manner (Wei et al., 2009; Wei et al., 2010). Sabutoclax
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Figure 7. Bone Marrow BC LSCs Are Sensi-
tive to Sabutoclax
(A) Representative TUNEL staining of BC-
engrafted bone marrow following treatment with
vehicle or sabutoclax.
(B) Relative engraftment of normal and BC
progenitors in bone marrow following vehicle and
sabutoclax treatment (5 mg/kg). Normal: vehicle
n = 6, sabutoclax n = 6; BC: vehicle n = 26, sab-
utoclax n = 27. Graph shows mean ± SEM and
statistical analysis by Mann-Whitney test.
(C) Fold change of normal stem cells in the bone
marrow after treatment with vehicle (n = 8); sabu-
toclax (10 mg/kg IV, biweekly for 4 doses [n = 8]);
dasatinib (50 mg/kg, daily oral gavage, 14 doses
total [n = 11]); or a combination of sabutoclax and
dasatinib (n = 10). Graph shows mean ± SEM.
(D) Fold change of normal stem cell in spleen
after treatment with vehicle (n = 8); sabutoclax
(10 mg/kg IV, biweekly for 4 doses [n = 8]); dasa-
tinib (50 mg/kg, daily oral gavage, 14 doses total
[n = 11]); or a combination of sabutoclax and
dasatinib (n = 10). Graph shows mean ± SEM.
(E) Relative engraftment of BC progenitors in
spleen, blood, and bone marrow following treat-
ment with vehicle (n = 9), sabutoclax (1.25 mg/kg,
n = 9), dasatinib (25 mg/kg, n = 9), and sabutoclax
in combination with dasatinib (n = 11). Graph
showsmean ± SEM. *, p < 0.05; **, p < 0.01; ***, p <
0.001 by Kruskal-Wallis test with Dunn’s post hoc
analysis.
(F) Survival of mice after being serially transplanted
with vehicle (n = 11)-, sabutoclax (n = 9)-, dasatinib
(n = 9)-, and combination (n = 13)-treated whole
bone marrow. Statistical analysis was performed
by log-rank test.
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Leukemia Stem Cell Elimination with a Pan-BCL2 Inhibitoralso sensitizes marrow-niche BC LSCs to TKI treatment,
suggesting that marrow-specific TKI protection is predicated,
at least in part, on BCL2 family expression in the niche
and can be overcome with a pan-BCL2 inhibitor. Also, unlike
dasatinib, sabutoclax targets quiescent self-renewing LSCs.
This is further evidenced by our observation that sabutoclax
combined with dasatinib significantly improves survival of
serially transplanted mice.
Although BCL2 inhibition has been previously explored in
CML, most studies have focused on CML cell lines (Kuroda
et al., 2006; Meng et al., 2007) or CD34+ cells grown in culture
(Mak et al., 2012) rather than self-renewing CML BC LSCs in
selective niches. Moreover, published reports do not address
the potential antithetical roles of BCL2 family splice-isoforms
or the role of the microenvironment in promoting LSC survival.
Treatment with ABT-737 (Kuroda et al., 2006; Mak et al., 2012),
a potent BCL2 and BCLXL inhibitor, does not inhibit MCL1L
or BFL1 (Oltersdorf et al., 2005; Wei et al., 2010), both of
which accelerate leukemogenesis (Beverly and Varmus, 2009),Cell Stem Cell 12, 316–3mediate resistance (Chen et al., 2007; Vo-
gler et al., 2009a; Yecies et al., 2010), and
are upregulated in CML progenitors
during progression from CP to BC.
Because inhibition of both subfamilies of
prosurvival BCL2 family proteins isnecessary for apoptosis initiation (Vogler et al., 2009b), inhibition
strategies that include MCL1 would be expected to be more
successful than those that target BCL2 alone (Placzek et al.,
2010). Recently, paired-end DNA sequencing analysis revealed
an intronic deletion polymorphism in the proapoptotic gene
BIM (BCL2-like 11), which generated a splice-isoform lacking
the BH3 domain and preventing BIM-induced apoptosis in
response to TKI therapy (Ng et al., 2012). Thus, pan-BCL2 inhibi-
tion may prove to be more effective at targeting TKI-resistant BC
LSCs that naturally express multiple BCL2 family proteins in
response to niche-dependent stimuli in vivo.
BCL2 family genes are regulated in a wide variety of hemato-
logic malignancies (Beverly and Varmus, 2009; Reed, 2008) and
solid tumors (Placzek et al., 2010). Moreover, CSC identified in
several tumor types (Hermann et al., 2010) could conceivably
rely on the expression of multiple prosurvival BCL2 family iso-
forms, making them candidates for pan-BCL2 inhibition as a vital
addition to combination CSC eradication therapy. Our findings
may also have relevance for the elimination of therapeutically28, March 7, 2013 ª2013 Elsevier Inc. 325
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Leukemia Stem Cell Elimination with a Pan-BCL2 Inhibitorrecalcitrant solid tumor CSCs where metastasis and survival in
the metastatic niche are mediated by prosurvival BCL2 family
expression (Mehlen and Puisieux, 2006). Thus, pan-BCL2 inhibi-
tion with sabutoclax could provide an important component of
combination therapies that target a broad array of CSCs residing
in protective niches.
EXPERIMENTAL PROCEDURES
Additional details and methods can be found in the Supplemental Experi-
mental Procedures.
Patient Sample Preparation and FACS Sorting
Normal cord blood and adult peripheral blood samples were purchased
from All Cells. CML samples were obtained from consenting patients at
the University of California San Diego, Stanford University, the University of
Toronto Health Network, MD Anderson, and the University of Bologna accord-
ing to protocols approved by the institutional review board. CD34+ cells were
initially purified by magnetic bead separation (MACS), followed by FACS
progenitor purification with human-specific CD34 and CD38 antibodies, as
previously described (Abrahamsson et al., 2009; Jamieson et al., 2004).
Peripheral bloodmononuclear cells were extracted from peripheral blood after
Ficoll density centrifugation and were then CD34+ selected, stained with fluo-
rescent conjugated antibodies, and analyzed and purified with the FACSAria
and FlowJo software as described previously (Abrahamsson et al., 2009;
Jamieson et al., 2004).
BCL2 Family Gene Splice-isoform Analysis
Normal or CML CD34+ cells were stained with a mouse antihuman BCL2
(Dako) monoclonal antibody and analyzed by FACS. qRT-PCR was performed
with the SYBR GreenER Two-Step qRT-PCR Kit (Invitrogen) for the detection
ofBCL2,MCL1,BCLX, andBFL1 isoforms in FACS-sorted normal versus CML
progenitors. Quantitative BCL2 isoform and apoptosis gene analysis was also
performed in FACS-sorted normal and CML progenitors by whole-transcrip-
tome RNA-seq.
BCL2 genes were also analyzed in engrafted CML cells. In brief, 20,000–
50,000 CD34+CD38+Lin cells were FACS-sorted from engrafted tissues
and analyzed with the use of isoform-specific qRT-PCR, as above, or
with the use of an RT-PCR apoptosis-pathway OpenArray nanoplate
(Invitrogen). BCL2 protein was also measured in engrafted tissue cells as
described above.
Quantitative RT-PCR
20,000–50,000 hematopoietic progenitor cells were sorted from the
indicated cell populations with the use of FACS; total RNA was isolated and
complementary DNA was synthesized as described previously (Abrahamsson
et al., 2009; Jamieson et al., 2004). qRT-PCRwas performed in duplicate on an
iCycler with the use of SYBR GreenER qPCR SuperMix (Invitrogen), 5 ng of
template mRNA, and 0.4mM of each forward and reverse primer. Splice-
isoform-specific primers were designed for BCL2, MCL1, BCLX, and BFL1,
and isoform specificity was confirmed by the sequencing of each PCR
product. Messenger RNA (mRNA) levels for each transcript were normalized
to HPRT and compared by the delta-delta Ct method.
SL and M2 Coculture and In Vitro Drug Treatment
Normal or CML CD34+ cells were selected and plated on confluent, mito-
mycin-C-treated SL and M2 cells along with different doses of BI-97C1
(sabutoclax). After 1 week of culture, human progenitor cells were quantified
by FACS and cells were plated in methylcellulose for colony-forming assays.
Colonies were scored after 2 additional weeks in culture.
Lentivirus Transduction
BCL2 mRNA expression was silenced with the use of shBCL2-encoding
SMARTvector 2.0 lentiviral particles (Thermo-Dharmacon, no. SK-003307).
The efficiency of shBCL2 and control lentiviral vectors was tested by transduc-
tion of 293T and K562 cell lines. Knockdown of50% of BCL2 transcripts was
confirmed by qRT-PCR. Cells transduced with lentiviral shBCL2 and shControl326 Cell Stem Cell 12, 316–328, March 7, 2013 ª2013 Elsevier Inc.were FACS-sorted into Methocult media (20–50 cells per well of a 96-well
plate, 5–10 wells per condition). Total colonies were counted for each condi-
tion after 2 weeks of culture, and BCL2 knockdown was measured in the
colonies.
Statistical Analysis
Statistical analyses were performed with the aid of Microsoft Excel, SAS 9.2,
and GraphPad Prism software, as indicated in the figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures,
seven figures, and six tables and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2012.12.011.
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